Raymond Miller Image

Raymond Miller

Partner; US Chair, Life Sciences Patent Development & Strategy

DLA Piper LLP

Ray Miller is a Partner and US Chair, Life Sciences Patent Development & Strategy at DLA Piper LLP.  Ray Miller is a trusted intellectual property advisor to clients in a wide range of spaces. He adds value to each client’s IP estate by providing clear and pragmatic guidance that allows for efficient navigation of IP opportunities. Ray helps clients identify, protect, secure and optimize the value of their IP by combining strategic patent prosecution with manufacturing and regulatory exclusivity strategies. Ray counsels materials science, pharmaceutical, medical device, biologics and digital therapeutics clients to allow them to obtain a sufficient return on their investment. Ray also manages freedom-to-operate, manufacturing and supply considerations on his clients’ behalf. His clients include private equity and venture capital funds, pharmaceutical and biotechnology firms, world-class medical and research facilities, and Fortune 500 companies with well-developed intellectual property portfolios.

Ray’s practice is transactional. He has led hundreds of due diligence projects and prepared all forms of IP agreements and opinions. He applies his deep understanding of the life and materials sciences in a diverse range of industries such as pharmaceuticals, biotechnology, energy, manufacturing, computer hardware, water and air purification, and specialty plastics and chemicals. Ray’s experience in pharmaceuticals and biotechnology extends to disciplines such as medicinal chemistry, genetics, nutraceuticals, proteomics, nanotechnology and tissue engineering.

Recent Articles by Raymond Miller

In Sickness and In Health: Comparing Patent Protection for Pharmaceuticals and Dietary Supplements

Once composition of matter claims have been obtained for a new compound, or the composition of matter claims for an old compound have expired, what is next? Securing additional patent protection usually entails obtaining claims to methods of treatment, methods of prevention or improvement, methods of maintaining health, and mechanisms of action. These paths diverge depending on whether the compound is being developed as a pharmaceutical (i.e., a drug or biologic) or a dietary supplement.

Past Events with Raymond Miller